Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint ...

Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...

As of that DCO, safety findings based on 55 patients who had received at least one treatment showed [²¹²Pb]VMT-α-NET continued to demonstrate a favorable safety profile, with no dose-limiting ...

First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability ...

Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.

Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant ...

Netflix has admitted it did not attribute any value to Warner Bros.’ video game business in its $82.7 billion acquisition deal, sparking concern for the future of everything from Mortal Kombat to ...

Singapore Airlines’ A350-900 Business Class seat comes with a plush blanket, a full-size pillow, noise-cancelling headphones, ...

Graham Holdings Company ( GHC) Analyst/Investor Day December 9, 2025 1:00 PM EST ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistan ...

TURKU, FI / ACCESS Newswire / December 8, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Significant efficacy observed in TP53-mutated patients with a 70% complete remission rate in the ...